{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:57:44Z","timestamp":1784257064830,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejso.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ejso.2016.12.008","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T18:31:51Z","timestamp":1484159511000},"page":"763-771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8828-1067","authenticated-orcid":false,"given":"S.","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tomokuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marubashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sakon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2016.12.008_bib1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2016.12.008_bib2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jso.21971","article-title":"Treatment of borderline cases for curative resection of biliary tract cancer","volume":"104","author":"Kobayashi","year":"2011","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.ejso.2016.12.008_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00534-008-0015-0","article-title":"Biliary tract cancer treatment: 5,584 results from the biliary tract cancer statistics registry from 1998 to 2004 in Japan","volume":"16","author":"Miyakawa","year":"2009","journal-title":"J\u00a0Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.ejso.2016.12.008_bib4","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00268-007-9001-y","article-title":"Surgical resection of hilar cholangiocarcinoma. Analysis of survival and postoperative complications","volume":"31","author":"Hasegawa","year":"2007","journal-title":"World J Surg"},{"key":"10.1016\/j.ejso.2016.12.008_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10147-013-0578-x","article-title":"A\u00a0single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer","volume":"19","author":"Yamanaka","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejso.2016.12.008_bib6","first-page":"703","article-title":"Comparison of 4-Weekly vs 3-Weekly gemcitabine as adjuvant chemotherapy following curative resection for biliary tract cancer: a prospective randomized controlled trial","volume":"2","author":"Kobayashi","year":"2011","journal-title":"J\u00a0Cancer Ther"},{"key":"10.1016\/j.ejso.2016.12.008_bib7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00280-014-2543-4","article-title":"Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study","volume":"74","author":"Kobayashi","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1016\/j.ejso.2016.12.008_bib8","doi-asserted-by":"crossref","first-page":"e0143072","DOI":"10.1371\/journal.pone.0143072","article-title":"Pharmacokinetic study of adjuvant gemcitabine therapy for biliary tract cancer following major hepatectomy (KHBO1101)","volume":"10","author":"Fujiwara","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2016.12.008_bib9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9610(97)00203-1","article-title":"Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma","volume":"174","author":"McMasters","year":"1997","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.ejso.2016.12.008_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/hep.15.43","article-title":"Neoadjuvant treatment of biliary tract cancer: state-of-the-art and new perspectives","volume":"3","author":"Imperatori","year":"2016","journal-title":"Hepat Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2016.12.008_bib11","first-page":"51","article-title":"Neoadjuvant chemoradiotherapy in gallbladder cancer","volume":"132","author":"de Aretxabala","year":"2004","journal-title":"Rev Med Chil"},{"issue":"1","key":"10.1016\/j.ejso.2016.12.008_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/07357900500449454","article-title":"A\u00a0phase I study of eniluracil\/5-FU in combination with radiation therapy for potentially resectable and\/or unresectable cancer of the pancreas and distal biliary tract","volume":"24","author":"Czito","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ejso.2016.12.008_bib13","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s11605-012-1935-1","article-title":"Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins","volume":"16","author":"Glazer","year":"2012","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"10","key":"10.1016\/j.ejso.2016.12.008_bib14","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2217\/fon.14.308","article-title":"Neoadjuvant chemotherapy in patients with locally advanced gall bladder cancer","volume":"11","author":"Sirohi","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejso.2016.12.008_bib15","first-page":"1866","article-title":"Phase I trial of neoadjuvant chemoradiation with gemcitabine and surgical resection for cholangiocarcinoma patients (NACRAC study)","volume":"58","author":"Katayose","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.ejso.2016.12.008_bib16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejso.2016.12.008_bib17","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/SLA.0b013e31829b3ce4","article-title":"Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer","volume":"258","author":"Takahashi","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2016.12.008_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/SLA.0b013e3181ad65cc","article-title":"Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer","volume":"250","author":"Ohigashi","year":"2009","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejso.2016.12.008_bib19","first-page":"335","article-title":"Clinicopathological features of surgically-resected biliary tract cancer following chemo-radiation therapy","volume":"36","author":"Kobayashi","year":"2016","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.ejso.2016.12.008_bib20","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-015-2908-3","article-title":"Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer","volume":"76","author":"Kobayashi","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejso.2016.12.008_bib21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/jso.21501","article-title":"Multi-detector computed tomography for preoperative prediction of postsurgical prognosis of patients with extrahepatic biliary cancer","volume":"101","author":"Kobayashi","year":"2010","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.ejso.2016.12.008_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jso.21811","article-title":"Diagnostic value of FDG-PET for lymph node metastasis and outcome of surgery for biliary cancer","volume":"103","author":"Kobayashi","year":"2011","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.ejso.2016.12.008_bib23","series-title":"Classification of biliary tract carcinoma","author":"Japanese Society of Biliary Surgery","year":"2003"},{"key":"10.1016\/j.ejso.2016.12.008_bib24","series-title":"International Union against Cancer, TNM classification of malignant tumors","author":"Sobin","year":"2010"},{"key":"10.1016\/j.ejso.2016.12.008_bib25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2016.12.008_bib26","first-page":"521","article-title":"Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report","volume":"107","author":"Makuuchi","year":"1990","journal-title":"Surgery"},{"key":"10.1016\/j.ejso.2016.12.008_bib27","first-page":"434","article-title":"Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization","volume":"21","author":"Nagino","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.ejso.2016.12.008_bib28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-127-8_Part_2-199710151-00064","article-title":"Estimating causal effects from large data sets using propensity scores","volume":"127","author":"Rubin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ejso.2016.12.008_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00534-011-0413-6","article-title":"Diagnostic ability of MDCT to assess right hepatic artery invasion by perihilar cholangiocarcinoma with left-sided predominance","volume":"19","author":"Fukami","year":"2012","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"issue":"2","key":"10.1016\/j.ejso.2016.12.008_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijsu.2012.12.006","article-title":"Clinicopathological features of long-term survivors for advanced biliary tract cancer and impact of the number of lymph nodes involved","volume":"11","author":"Kobayashi","year":"2013","journal-title":"Int J Surg"},{"issue":"5","key":"10.1016\/j.ejso.2016.12.008_bib31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s005340200076","article-title":"Biliary tract cancer treatment: results from the biliary tract cancer statistics registry in Japan","volume":"9","author":"Nagakawa","year":"2002","journal-title":"J\u00a0Hepatobiliary Pancreat Surg"},{"issue":"1","key":"10.1016\/j.ejso.2016.12.008_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1620\/tjem.217.1","article-title":"Correct diagnosis of vascular encasement and longitudinal extension of hilar cholangiocarcinoma by four-channel multidetector-row computed tomography","volume":"217","author":"Okumoto","year":"2009","journal-title":"Tohoku J Exp Med"},{"issue":"1","key":"10.1016\/j.ejso.2016.12.008_bib33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/bjs.5920","article-title":"Computed tomography evaluation of regional lymph node metastases in patients with biliary cancer","volume":"95","author":"Noji","year":"2008","journal-title":"Br J Surg"},{"issue":"3","key":"10.1016\/j.ejso.2016.12.008_bib34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.surg.2014.09.022","article-title":"Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence","volume":"157","author":"Takahashi","year":"2015","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.ejso.2016.12.008_bib35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bjc.6605211","article-title":"Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study \u2013 the UK ABC-01 Study","volume":"101","author":"Valle","year":"2009","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2016.12.008_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00280-014-2648-9","article-title":"A\u00a0multi-institution phase II study of gemcitabine\/cisplatin\/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)","volume":"75","author":"Kanai","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejso.2016.12.008_bib37","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/jso.23767","article-title":"Prognostic impact of tumoral and\/or peri-tumoral stromal SPARC expressions after surgery in patients with biliary tract cancer","volume":"110","author":"Nakashima","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.ejso.2016.12.008_bib38","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ejca.2012.12.002","article-title":"Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer","volume":"49","author":"Yamada","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2016.12.008_bib39","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/cas.12652","article-title":"BRCA\/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer","volume":"106","author":"Nakashima","year":"2015","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.ejso.2016.12.008_bib40","doi-asserted-by":"crossref","first-page":"e0145985","DOI":"10.1371\/journal.pone.0145985","article-title":"Histone deacetylase inhibitor suppresses epithelial-mesenchymal transition and attenuates chemoresistance in biliary tract cancer","volume":"11","author":"Sakamoto","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejso.2016.12.008_bib41","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1158\/1535-7163.MCT-06-0686","article-title":"Tumor-stroma interactions in pancreatic ductal adenocarcinoma","volume":"6","author":"Mahadevan","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejso.2016.12.008_bib42","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/bjc.2013.415","article-title":"Stromal disrupting effects of nab-paclitaxel in pancreatic cancer","volume":"109","author":"Alvarez","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2016.12.008_bib43","first-page":"45","article-title":"Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1","volume":"17","author":"de Lorenzo","year":"2003","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.ejso.2016.12.008_bib44","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/1471-2407-14-360","article-title":"TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group","volume":"14","author":"J\u00f8rgensen","year":"2014","journal-title":"BMC Cancer"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798317300355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798317300355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T22:08:48Z","timestamp":1601330928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798317300355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0748798317300355"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2016.12.008","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology (EJSO)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2016.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}